↑ Kuschner, R. A.; Russell, K. L.; Abuja, M.; Bauer, K. M.; Faix, D. J.; Hait, H.; Henrick, J.; Jacobs, M.; Liss, A.; Lynch, J. A.; Liu, Q.; Lyons, A. G.; Malik, M.; Moon, J. E.; Stubbs, J.; Sun, W.; Tang, D.; Towle, A. C.; Walsh, D. S.; Wilkerson, D.; Adenovirus Vaccine Efficacy Trial Consortium (2013). “A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. Military recruits”. Vaccine. 31 (28): 2963–2971. doi:10.1016/j.vaccine.2013.04.035. PMID23623865.
↑ Kim, D. S.; Nam, J. H. (2010). “Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines”. Expert Opinion on Biological Therapy. 10 (2): 179–190. doi:10.1517/14712590903379502. PMID20088713.
↑ Zhu, F. C.; Liang, Z. L.; Li, X. L.; Ge, H. M.; Meng, F. Y.; Mao, Q. Y.; Zhang, Y. T.; Hu, Y. M.; Zhang, Z. Y.; Li, J. X.; Gao, F.; Chen, Q. H.; Zhu, Q. Y.; Chu, K.; Wu, X.; Yao, X.; Guo, H. J.; Chen, X. Q.; Liu, P.; Dong, Y. Y.; Li, F. X.; Shen, X. L.; Wang, J. Z. (2013). “Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial”. The Lancet. 381 (9871): 1037. doi:10.1016/S0140-6736(12)61764-4.
↑ Hanabuchi, S.; Ohashi, T.; Koya, Y.; Kato, H.; Hasegawa, A.; Takemura, F.; Masuda, T.; Kannagi, M. (2001). “Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: Peptide-induced T-cell immunity”. Journal of the National Cancer Institute. 93 (23): 1775–1783. doi:10.1093/jnci/93.23.1775. PMID11734593.
↑ De Thé, G.; Bomford, R.; Kazanji, M.; Ibrahim, F. (1994). “Human T cell lymphotropic virus: Necessity for and feasibility of a vaccine”. Ciba Foundation symposium. 187: 47–55, discussion 55–60. PMID7796676.
↑ Hampton, T. (2006). “Marburg Vaccine Shows Promise: Offers Postexposure Protection in Monkeys”. JAMA: the Journal of the American Medical Association. 295 (20): 2346–2310. doi:10.1001/jama.295.20.2346.
↑ Shivakumar, K. M.; Vidya, S. K.; Chandu, G. N. (2009). “Dental caries vaccine”. Indian journal of dental research: official publication of Indian Society for Dental Research. 20 (1): 99–106. doi:10.4103/0970-9290.49066. PMID19336869.
↑ Rudoler, N.; Baneth, G.; Eyal, O.; Van Straten, M.; Harrus, S. (2012). “Evaluation of an attenuated strain of Ehrlichia canis as a vaccine for canine monocytic ehrlichiosis”. Vaccine. 31 (1): 226–233. doi:10.1016/j.vaccine.2012.10.003. PMID23072894.
↑ Bagnoli, F.; Bertholet, S.; Grandi, G. (2012). “Inferring Reasons for the Failure of Staphylococcus aureus Vaccines in Clinical Trials”. Frontiers in Cellular and Infection Microbiology. 2. doi:10.3389/fcimb.2012.00016.
↑ Guilherme, L.; Ferreira, F. M.; Köhler, K. F.; Postol, E.; Kalil, J. (2013). “A Vaccine against Streptococcus pyogenes”. American Journal of Cardiovascular Drugs. 13 (1): 1–4. doi:10.1007/s40256-013-0005-8. PMID23355360.
↑ Cullen, P. A.; Cameron, C. E. (2006). “Progress towards an effective syphilis vaccine: The past, present and future”. Expert Review of Vaccines. 5 (1): 67–80. doi:10.1586/14760584.5.1.67. PMID16451109.
↑ Conlan, J. W. (2011). “Tularemia vaccines: Recent developments and remaining hurdles”. Future Microbiology. 6 (4): 391–405. doi:10.2217/fmb.11.22. PMID21526941.
↑ Titball, R. W.; Williamson, E. D. (2004). “Yersinia pestis (plague) vaccines”. Expert Opinion on Biological Therapy. 4 (6): 965–973. doi:10.1517/14712598.4.6.965. PMID15174978.
